Illumina announces CEO transition plan as Francis deSouza resigns

Illumina announces CEO transition plan as Francis deSouza resigns


Francis deSouza, chief executive officer of Illumina Inc., during a panel session on day three of the World Economic Forum (WEF) in Davos, Switzerland, on Thursday, Jan. 19, 2023.

Stefan Wermuth | Bloomberg | Getty Images

Illumina on Sunday announced its board of directors has accepted the resignation of CEO Francis deSouza, just weeks after activist investor Carl Icahn failed to oust him from the biotech company.

The board of directors is searching for a new CEO and is considering both internal and external candidates, according to a release. Charles Dadswell, Illumina’s senior vice president and general counsel, will act as CEO in the interim.

DeSouza’s resignation is effective immediately, but he will stay on in an advisory capacity until July 31.

“It has been the privilege of a lifetime to serve Illumina,” deSouza said in the release. “We have made great progress together, but I believe we are still at the very beginning of the impact Illumina will have on human health by unlocking the power of the genome.”

Illumina, known for its DNA sequencing and array-based technology, has been in a heated proxy fight with Icahn, who owns a 1.4% stake in the company.

Icahn has accused Illumina’s executive management and board of poor oversight, particularly with regard to the company’s controversial $7.1 billion acquisition of cancer test maker Grail in 2021. Similarly, in an open letter to Illumina shareholders in April, Icahn accused deSouza of “desperately, hilariously and, most of all, unsuccessfully” trying to spin “decidedly mediocre” quarterly results during a press tour.

In late May, Icahn had urged shareholders to vote off deSouza and Chairman John Thompson from the nine-member board. Shareholders booted Thompson, but deSouza held onto his role until Sunday.



Source

Anthropic launches Claude Life Sciences to give researchers an AI efficiency boost
Health

Anthropic launches Claude Life Sciences to give researchers an AI efficiency boost

Dario Amodei, Anthropic CEO, speaking on CNBC’s Squawk Box outside the World Economic Forum in Davos, Switzerland on Jan. 21st, 2025. Gerry Miller | CNBC Anthropic on Monday announced Claude for Life Sciences, a new offering for researchers to use the company’s artificial intelligence technology in the advancement of scientific discovery.  Claude for Life Sciences is […]

Read More
Eli Lilly and Novo Nordisk stocks fall as Trump says he wants 0 price for GLP-1s
Health

Eli Lilly and Novo Nordisk stocks fall as Trump says he wants $150 price for GLP-1s

Shares of Eli Lilly and Novo Nordisk dropped Friday, after President Donald Trump said his administration aims to cut the cost of brand name GLP-1 weight loss drugs to $150 per month, a fraction of their current list price. “In London, you’d buy a certain drug for $130 and even less than that … $88 […]

Read More
Trump announces efforts to expand access to IVF drugs
Health

Trump announces efforts to expand access to IVF drugs

U.S. President Donald Trump delivers remarks before signing an executive order on expanding access to IVF at his Mar-a-Lago resort on Feb. 18, 2025 in Palm Beach, Florida. Joe Raedle | Getty Images President Donald Trump on Thursday announced two new efforts to expand the availability of in vitro fertilization, the first concrete step from his […]

Read More